The New York Obesity Nutrition Research Center

 Study

Treatment of Diabetes after gastric bypass with Sitagliptin

Study Type

Treatment of Diabetes after gastric bypass with Sitagliptin (IRB#: 11-156, approved November 28, 2011)

Study Purpose

Assess the efficacy, safety, tolerability and effect on post-prandial glood glucose and satiety of sitagliptin (100 mg/d) monotherapy for the treatment of recurrent, persistent or newly diagnosed type 2 diabetes in patients after gastric bypass surgery for weight loss.

Study Design

4 study visits
  • Day 1 – screening interview
  • Day 2 – Meal study #1
  • Day 3 – Mid-point check-in interview
  • Day 4 – Meal study #2

Study Qualifications

  • Had gastric bypass surgery more than 1 year ago
  • Had type II diabetes before gastric bypass surgery
  • Currently has type 2 diabetes \
  • Non-smoker at least 6 months prior to study
  • All ethnic groups welcome

Study Duration

4 to 6 weeks 

Study Benefits

Learn more about the efficacy of sitagliptin (100 mg/d)  for the treatment of recurrent, persistent or newly diagnosed type 2 diabetes in patients after gastric bypass surgery for weight loss.

You will receive up to $300 in compensation for your time.

Study Contact

Interested?
Please call Margaret Sala (msala@chpnet.org) at 212-523-3503
or
Carolina Espinosa (cespinosa@chpnet.org) at 212-523-3581.

Copyright 2010, New York Obesity Nutrition Research Center. 
All Rights Reserved.